Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib

Por Krause G, Hassenrück F, Hallek M
Publicado em 2018-08-01

Necrotizing Pneumonia Caused by Panton-Valentine Leucocidin-Producing Staphylococcus aureus Originating from a Bartholin's Abscess

Por Jung, N., Lehmann, C., Hellmann, M., Seifert, H., Valter, M. M., Hallek, M., Fätkenheuer, G., Kochanek, M.
Publicado em 2008

Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours

Por Coutelle, O, Schiffmann, L M, Liwschitz, M, Brunold, M, Goede, V, Hallek, M, Kashkar, H, Hacker, U T
Publicado no Br J Cancer (2015)

Factors Influencing Pharmacokinetics of Prophylactic Posaconazole in Patients Undergoing Allogeneic Stem Cell Transplantation

Por Kohl, V., Müller, C., Cornely, O. A., Abduljalil, K., Fuhr, U., Vehreschild, J. J., Scheid, C., Hallek, M., Rüping, M. J. G. T.
Publicado em 2010

CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells

Por Sauer, M, Schuldner, M, Hoffmann, N, Cetintas, A, Reiners, K S, Shatnyeva, O, Hallek, M, Hansen, H P, Gasser, S, von Strandmann, E P
Publicado no Oncogene (2017)

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205

Por Hoehler, T, von Wichert, G, Schimanski, C, Kanzler, S, Moehler, M H, Hinke, A, Seufferlein, T, Siebler, J, Hochhaus, A, Arnold, D, Hallek, M, Hofheinz, R, Hacker, U T
Publicado em 2013

A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition

Por Schiffmann, L M, Brunold, M, Liwschitz, M, Goede, V, Loges, S, Wroblewski, M, Quaas, A, Alakus, H, Stippel, D, Bruns, C J, Hallek, M, Kashkar, H, Hacker, U T, Coutelle, O
Publicado no Br J Cancer (2017)

Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab

Por Freeman, C L, Dixon, M, Houghton, R, Kreuzer, K-A, Fingerle-Rowson, G, Herling, M, Humphrey, K, Böttcher, S, de Costa, C S, Iglesias, V, Stilgenbauer, S, Gribben, J, Hallek, M, Goede, V
Publicado no Leukemia (2016)

Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy

Por Goede, V, Coutelle, O, Neuneier, J, Reinacher-Schick, A, Schnell, R, Koslowsky, T C, Weihrauch, M R, Cremer, B, Kashkar, H, Odenthal, M, Augustin, H G, Schmiegel, W, Hallek, M, Hacker, U T
Publicado em 2010

Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis

Por Cornely, O. A., Vehreschild, J. J., Vehreschild, M. J. G. T., Würthwein, G., Arenz, D., Schwartz, S., Heussel, C. P., Silling, G., Mahne, M., Franklin, J., Harnischmacher, U., Wilkens, A., Farowski, F., Karthaus, M., Lehrnbecher, T., Ullmann, A. J., Hallek, M., Groll, A. H.
Publicado em 2011

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab

Por Fink, A M, Böttcher, S, Ritgen, M, Fischer, K, Pflug, N, Eichhorst, B, Wendtner, C-M, Winkler, D, Bühler, A, Zenz, T, Staib, P, Mayer, J, Hensel, M, Hopfinger, G, Wenger, M, Fingerle-Rowson, G, Döhner, H, Kneba, M, Stilgenbauer, S, Busch, R, Hallek, M
Publicado em 2013

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial

Por Bühler, A, Wendtner, C-M, Kipps, T J, Rassenti, L, Fraser, G A M, Michallet, A-S, Hillmen, P, Dürig, J, Gregory, S A, Kalaycio, M, Aurran-Schleinitz, T, Trentin, L, Gribben, J G, Chanan-Khan, A, Purse, B, Zhang, J, De Bedout, S, Mei, J, Hallek, M, Stilgenbauer, S
Publicado no Blood Cancer J (2016)

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research In...

Por Rawstron, A C, Fazi, C, Agathangelidis, A, Villamor, N, Letestu, R, Nomdedeu, J, Palacio, C, Stehlikova, O, Kreuzer, K-A, Liptrot, S, O'Brien, D, de Tute, R M, Marinov, I, Hauwel, M, Spacek, M, Dobber, J, Kater, A P, Gambell, P, Soosapilla, A, Lozanski, G, Brachtl, G, Lin, K, Boysen, J, Hanson, C, Jorgensen, J L, Stetler-Stevenson, M, Yuan, C, Broome, H E, Rassenti, L, Craig, F, Delgado, J, Moreno, C, Bosch, F, Egle, A, Doubek, M, Pospisilova, S, Mulligan, S, Westerman, D, Sanders, C M, Emerson, R, Robins, H S, Kirsch, I, Shanafelt, T, Pettitt, A, Kipps, T J, Wierda, W G, Cymbalista, F, Hallek, M, Hillmen, P, Montserrat, E, Ghia, P
Publicado no Leukemia (2016)